AbbVie (ABBV) director awarded 155 stock equivalent units as fees

Rhea-AI Filing Summary

RAPP EDWARD J reported acquisition or exercise transactions in this Form 4 filing.

AbbVie Inc. director Edward J. Rapp received a grant of 155 Stock Equivalent Units on March 31, 2026. The units were credited as director fees at a reference price of $217.49 per unit and are linked to AbbVie common stock performance.

Following this grant, Rapp holds a reported total of 28,865 Stock Equivalent Units. These units are maintained in a grantor trust established by the director and are generally paid in cash at age 65 or upon retirement from the board, with value tracking AbbVie stock, including a dividend reinvestment feature.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider RAPP EDWARD J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Equivalent Units	155	$217.49	$34K

Holdings After Transaction: Stock Equivalent Units — 28,865 shares (Direct)

Footnotes (1)

1. Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Key Figures

Stock Equivalent Units granted: 155 units Reference price per unit: $217.49 per unit Total Stock Equivalent Units after grant: 28,865 units

3 metrics

Stock Equivalent Units granted 155 units Director grant on March 31, 2026

Reference price per unit $217.49 per unit Grant valuation for Stock Equivalent Units

Total Stock Equivalent Units after grant 28,865 units Director’s reported balance following the award

Key Terms

Stock Equivalent Units, grantor trust, dividend reinvestment feature

3 terms

Stock Equivalent Units financial

"Director fees credited to a stock equivalent unit account under a grantor trust"

Stock equivalent units are financial claims or instruments that are treated as if they were actual shares for purposes like calculating ownership, dilution, and earnings per share. Think of them as promises or placeholders for future slices of company pie—options, restricted units, or convertible securities—that don’t yet sit on the table but will reduce each existing slice when converted. Investors track them because they change how much of a company each share really represents and can affect valuation and voting power.

grantor trust financial

"under a grantor trust established by the director and paid, in cash"

A grantor trust is a legal arrangement where the person who puts assets into the trust keeps enough control or rights that, for tax and legal purposes, those assets are treated as still belonging to that person. For investors, that matters because income, gains and losses generated by the trust typically flow through to the grantor (or directly to investors) for tax reporting and distributions, affecting after-tax returns and cash flow predictability — think of it like a mailbox that forwards all the mail back to the sender rather than holding it inside.

dividend reinvestment feature financial

"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RAPP EDWARD J

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Equivalent Units	$217.49	03/31/2026		A		155		(1)	(1)	Common Stock	155	$217.49	28,865(2)	D

Explanation of Responses:

1. Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

	/s/ T.O. Odutayo, Attorney-in-Fact for Edward J. Rapp	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did AbbVie (ABBV) director Edward J. Rapp report?

Edward J. Rapp reported receiving a grant of 155 Stock Equivalent Units tied to AbbVie common stock. These units represent director fees credited to a stock-equivalent account, rather than an open-market stock purchase or sale, and track AbbVie’s share performance over time.

At what price were Edward J. Rapp’s AbbVie (ABBV) stock equivalent units valued?

The 155 Stock Equivalent Units were valued at $217.49 per unit for accounting purposes. This reference price is used to determine the number of units credited as director fees and reflects AbbVie’s share value used in the compensation calculation.

How many AbbVie (ABBV) stock equivalent units does Edward J. Rapp hold after this grant?

After the March 31, 2026 grant, Edward J. Rapp holds 28,865 Stock Equivalent Units. This balance includes the newly awarded 155 units and additional units previously accumulated, including those acquired through a dividend reinvestment feature linked to AbbVie stock.

How and when are AbbVie (ABBV) stock equivalent units for directors paid out?

The Stock Equivalent Units are credited to an account under a grantor trust established by the director and are generally paid out in cash at age 65 or upon retirement from the board, based on AbbVie’s stock performance over the holding period.

Do AbbVie (ABBV) stock equivalent units include reinvested dividends?

Yes. The reported balance of Stock Equivalent Units includes units acquired through a dividend reinvestment feature. This means dividends notionally paid on AbbVie stock are reinvested into additional stock equivalent units, further linking compensation to long-term share performance.